rss

Coronavirus – Some Remdesivir news crossing – FDA warns on reduced effectiveness

US Food and Drug Administration (FDA) is warning about a newly discovered potential drug interaction related to the investigational antiviral drug remdesivir

  • Based on a recently completed non-clinical laboratory study, the FDA is revising the fact sheet for health care providers that accompanies the drug to state that co-administration of remdesivir and chloroquine phosphate or hydroxychloroquine sulfate is not recommended as it may result in reduced antiviral activity of remdesivir.
ps. I am not a pharmaceutical PhD (yet 😀 ) so just passing this along, K? Report via Market Watch
Hopes are high for Remdesivir, which has received emergency use authorization for the treatment of hospitalized COVID-19 patients with severe disease.

Early data on Gilead coronavirus medicine remdesivir is very encouraging

Antiviral medicine remdesivir is being used to treat cov1 COVID-19 patients at a Chicago hospital,

A small study only, and note: The lack of a control arm in the study could make interpreting the results more challenging, so not leaping to conclusions:
  • The University of Chicago Medicine recruited 125 people with Covid-19
  • two Phase 3 clinical trials
  • 113 had severe disease
  • All the patients been treated with daily infusions of remdesivir
  • “The best news is that most of our patients have already been discharged, which is great. We’ve only had two patients perish,” said Kathleen Mullane, the University of Chicago infectious disease specialist overseeing the remdesivir studies for the hospital.
Pic via Wikipedia:
Antiviral medicine remdesivir is being used to treat cov1 COVID-19 patients at a Chicago hospital, 
Go to top